Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Chinese Patent Office
McKinsey
Dow
Federal Trade Commission
Covington
UBS
Deloitte
Farmers Insurance
Fuji

Generated: October 20, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,413,980

« Back to Dashboard

Which drugs does patent 6,413,980 protect, and when does it expire?


Patent 6,413,980 protects ELIQUIS and is included in one NDA. There has been one Paragraph IV challenge on Eliquis.

This patent has twenty-six patent family members in twenty-four countries.

Summary for Patent: 6,413,980

Title: Nitrogen containing heterobicycles as factor Xa inhibitors
Abstract:The present application describes nitrogen containing heterobicyclics and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.
Inventor(s): Fevig; John M. (Lincoln University, PA), Cacciola; Joseph (Newark, DE), Clark; Charles G. (Cherry Hill, NJ), Han; Qi (Wilmington, DE), Lam; Patrick Yuk Sun (Chadds Ford, PA), Pinto; Donald J.P. (Kennett Square, PA), Pruitt; James R. (Landenberg, PA), Quan; Mimi L. (Newark, DE), Rossi; Karen A. (Newark, DE)
Assignee: Bristol-Myers Squibb Pharma Company (Princeton, NJ)
Application Number:09/470,326
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Bristol Myers Squibb
ELIQUIS
apixaban
TABLET;ORAL202155-001Dec 28, 2012RXYesNo► Subscribe► SubscribeYY PROPHYLAXIS OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM
Bristol Myers Squibb
ELIQUIS
apixaban
TABLET;ORAL202155-001Dec 28, 2012RXYesNo► Subscribe► SubscribeYY TREATMENT OF DEEP VEIN THROMBOSIS (DVT)
Bristol Myers Squibb
ELIQUIS
apixaban
TABLET;ORAL202155-001Dec 28, 2012RXYesNo► Subscribe► SubscribeYY TREATMENT OF PULMONARY EMBOLISM (PE)
Bristol Myers Squibb
ELIQUIS
apixaban
TABLET;ORAL202155-001Dec 28, 2012RXYesNo► Subscribe► SubscribeYY REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM
Bristol Myers Squibb
ELIQUIS
apixaban
TABLET;ORAL202155-002Dec 28, 2012RXYesYes► Subscribe► SubscribeYY REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM
Bristol Myers Squibb
ELIQUIS
apixaban
TABLET;ORAL202155-002Dec 28, 2012RXYesYes► Subscribe► SubscribeYY TREATMENT OF DEEP VEIN THROMBOSIS (DVT)
Bristol Myers Squibb
ELIQUIS
apixaban
TABLET;ORAL202155-002Dec 28, 2012RXYesYes► Subscribe► SubscribeYY TREATMENT OF PULMONARY EMBOLISM (PE)
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,413,980

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,673,810 Imidazo-heterobicycles as factor Xa inhibitors► Subscribe
6,858,616 Nitrogen containing heterobicycles as factor Xa inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,413,980

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina024242► Subscribe
Austria280171► Subscribe
Australia2371700► Subscribe
Australia759711► Subscribe
Brazil9917080► Subscribe
Canada2349330► Subscribe
China100340559► Subscribe
China1391575► Subscribe
Germany69921358► Subscribe
Denmark1140941► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Baxter
Chubb
Julphar
Mallinckrodt
Federal Trade Commission
Farmers Insurance
Johnson and Johnson
Chinese Patent Office
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot